Cannabinoids Clinical Trials Conditions DEA 
Cannabis Law Report
NOVEMBER 22, 2019
MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. ”We are pleased with the DEA ‘s cooperation and support to facilitate our company mission to service the unmet needs of patients suffering from these chronic diseases.”
Veriheal
APRIL 11, 2022
Drug Enforcement Agency (DEA). We could potentially develop north of 11,000 drugs that are cannabinoid-based. According to the company’s CEO, George Hodgin, “federally legal FDA- and DEA-approved cannabis-based drugs will absolutely upend the traditional pharmaceutical market.”. Is the future exciting? Absolutely.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MAY 29, 2022
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. Clinical Trials and Human Subject Protections. Before the drug approval process even begins, sponsors must initiate clinical investigations by first filing an Investigational New Drug Application (IND) with FDA.
CannaMD
AUGUST 8, 2020
In honor of National CBD Day, CannaMD wants to clear up some cannabinoid confusion once and for all. However, many of these products contain a number of other cannabinoids as well. To understand cannabinoids, we need to take a closer look at the endocannabinoid system.
SpeedWeed
MARCH 18, 2021
A fourth group received a placebo with almost zero active cannabinoids. Given the topical nature of the current trial and its relevance for public policy on medical cannabis, participants might have been biased to report positive effects regardless of condition. Wasn’t the DEA going to let others grow research-grade cannabis?
Veriheal
AUGUST 31, 2020
However, social and economic barriers like racial stereotypes and lack of access to care centers have historically barred Hispanic community members from seeking medical cannabis and participating in clinical trials. This can help change the way people look at the substance.
Veriheal
JUNE 29, 2021
In order to legally access other therapies including nature-based options such as psilocybin , you must gain access under a Right to Try law which requires you to have a terminal condition. The lawsuit came after the DEA denied their application to utilize a synthetic form of psilocybin under the RTT laws.
Expert insights. Personalized for you.
66 
Let's personalize your content